10X Genomics Hits New 52-Week High of $26.44, Reflecting Strong Growth

10X Genomics, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 26.44 on April 17, 2026. This achievement marks a notable increase from its 52-week low of USD 7.25, reflecting a substantial upward trend in the stock's performance over the past year. In the last year, 10X Genomics has recorded a performance increase of 17.58%, although it trails behind the S&P 500's performance of 34.89%. The company's market capitalization stands at USD 2,132 million, indicating its position within the small-cap segment of the market. Despite being a loss-making entity, 10X Genomics maintains a price-to-book ratio of 2.68. The company currently does not offer a dividend, and its debt-to-equity ratio is reported at -0.64, alongside a return on equity of -10.80%. This recent price movement highlights the stock's volatility and the dynamic nature of the biotechnology industry.